Real-World Application of Anti-β-Amyloid Monoclonal Antibodies Untangling Eligibility

The Alzheimer disease (AD) treatment landscape is rapidly evolving. Planning is actively underway to bring newly approved amyloid-lowering monoclonal antibodies for early AD into clinical practice.1-4 Full Food and Drug Administration (FDA) approval of lecanemab on July 6, 2023, and subsequent coverage by the Center for Medicare Services has opened a new era in the diagnosis and treatment of AD that poses significant challenges for providers, payers, and health care systems. Given the large number of patients with early AD potentially eligible for this treatment, a major question is how to estimate the number likely to qualify for treatment.5

Automated summary

The treatment landscape for Alzheimer's disease is evolving rapidly with the approval of amyloid-lowering monoclonal antibodies for early AD. The full FDA approval of lecanemab and subsequent coverage by the Center for Medicare Services have opened a new era in the diagnosis and treatment of AD, posing challenges for providers, payers, and healthcare systems.